Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2012

Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2012', provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) therapeutic pipeline. This report provides information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure). 'Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chronic Kidney Disease (Chronic Renal Failure).
- A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Chronic Kidney Disease (Chronic Renal Failure) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Kidney Disease (Chronic Renal Failure) Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) 9
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Development by Companies 11
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 17
Comparative Analysis 17
Mid Clinical Stage Products 18
Comparative Analysis 18
Early Clinical Stage Products 19
Comparative Analysis 19
Discovery and Pre-Clinical Stage Products 20
Comparative Analysis 20
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Products under Development by Companies 21
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Chronic Kidney Disease (Chronic Renal Failure) Therapeutics Development 26
Abbott Laboratories 26
Amgen Inc. 27
Eli Lilly and Company 28
Isis Pharmaceuticals, Inc. 29
Quark Pharmaceuticals, Inc. 30
Merck & Co., Inc. 31
FibroGen, Inc. 32
MD Scientific, LLC 33
Astellas Pharma Inc. 34
Kureha Corporation 35
Cyclacel Pharmaceuticals Inc. 36
Nile Therapeutics, Inc. 37
Alexion Pharmaceuticals, Inc. 38
Panacea Biotec Limited 39
Pieris AG 40
Hawthorn Pharmaceuticals, Inc. 41
Promedior, Inc. 42
Reata Pharmaceuticals, Inc. 43
Angion Biomedica Corp. 44
Thrasos, Inc. 45
Concert Pharmaceuticals, Inc. 46
CorMedix, Inc. 47
Vitae Pharmaceuticals, Inc. 48
Stelic Institute & Co. 49
Zenyaku Kogyo Co., Ltd. 50
Ardelyx, Inc. 51
Sorbent Therapeutics, Inc. 52
InVasc Therapeutics, Inc. 53
Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Combination Products 55
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 61
YM533 - Drug Profile 61
LY2127399 - Drug Profile 62
FG-3019 - Drug Profile 64
Sensipar - Drug Profile 66
Bardoxolone Methyl - Drug Profile 68
Bardoxolone Methyl - Drug Profile 70
PRS-080 - Drug Profile 72
Soliris - Drug Profile 74
CU-NP - Drug Profile 76
Seliciclib - Drug Profile 77
Kremezin - Drug Profile 79
THR-123 - Drug Profile 81
siRNA For Chronic Diseases - Drug Profile 82
G Family Inhibitor For CKD - Drug Profile 83
VTP-27999 - Drug Profile 84
KAI-4169 IV - Drug Profile 86
KAI-4169 IV - Drug Profile 87
Sodium Bicarbonate - Drug Profile 88
CLP 1001 - Drug Profile 89
CLP 1004 - Drug Profile 90
18B Glycyrrhetinic Acid - Drug Profile 91
Everolimus - Drug Profile 92
Benazepril - Drug Profile 93
Valsartan - Drug Profile 95
Benazepril + Valsartan - Drug Profile 97
ABT-627 - Drug Profile 99
Folate + Pyridoxine + Cyanocobalamin - Drug Profile 100
Renagel + Cinacalcet - Drug Profile 102
Irbesartan - Drug Profile 103
Eplerenone - Drug Profile 104
LY2382770 - Drug Profile 105
Neo-Kidney Augment - Drug Profile 106
MK3102 - Drug Profile 107
CRMD-001 - Drug Profile 108
Simulect + Myfortic + Certican + Prednisolone - Drug Profile 109
IDEC-C2B8 - Drug Profile 111
Siran - Drug Profile 112
Ramipril + Telmisartan - Drug Profile 113
Silymarin - Drug Profile 114
haw Nuv15 - Drug Profile 115
haw Nuv16 - Drug Profile 116
INV-144 - Drug Profile 117
CYC065 - Drug Profile 118
N-Acetylcysteine - Drug Profile 119
LY2623091 - Drug Profile 120
Renvela - Drug Profile 121
Zemplar - Drug Profile 122
CTP-499 - Drug Profile 123
Subcutaneous rhPTX-2 - Drug Profile 125
ISIS-CRP - Drug Profile 126
ANG-3070 - Drug Profile 127
ANG-4011 - Drug Profile 128
RDX-002 - Drug Profile 129
Drug For Chronic Kidney Disease - Drug Profile 130
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Drug Profile Updates 131
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Discontinued Products 152
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics - Dormant Products 153
Chronic Kidney Disease (Chronic Renal Failure) – Product Development Milestones 156
Featured News & Press Releases 156
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 165
Disclaimer 165

List of Tables
Number of Products Under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2012 13
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H2 2012 14
Number of Products under Development by Companies, H2 2012 16
Number of Products under Development by Companies, H2 2012 (Contd..1) 17
Number of Products under Development by Companies, H2 2012 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2012 20
Comparative Analysis by Late Stage Development, H2 2012 21
Comparative Analysis by Mid Clinical Stage Development, H2 2012 22
Comparative Analysis by Early Clinical Stage Development, H2 2012 23
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Development by Companies, H2 2012 (Contd..1) 26
Products under Development by Companies, H2 2012 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Abbott Laboratories, H2 2012 30
Amgen Inc., H2 2012 31
Eli Lilly and Company, H2 2012 32
Isis Pharmaceuticals, Inc., H2 2012 33
Quark Pharmaceuticals, Inc., H2 2012 34
Merck & Co., Inc., H2 2012 35
FibroGen, Inc., H2 2012 36
MD Scientific, LLC, H2 2012 37
Astellas Pharma Inc., H2 2012 38
Kureha Corporation, H2 2012 39
Cyclacel Pharmaceuticals Inc., H2 2012 40
Nile Therapeutics, Inc., H2 2012 41
Alexion Pharmaceuticals, Inc., H2 2012 42
Panacea Biotec Limited, H2 2012 43
Pieris AG, H2 2012 44
Hawthorn Pharmaceuticals, Inc., H2 2012 45
Promedior, Inc., H2 2012 46
Reata Pharmaceuticals, Inc., H2 2012 47
Angion Biomedica Corp., H2 2012 48
Thrasos, Inc., H2 2012 49
Concert Pharmaceuticals, Inc., H2 2012 50
CorMedix, Inc., H2 2012 51
Vitae Pharmaceuticals, Inc., H2 2012 52
Stelic Institute & Co., H2 2012 53
Zenyaku Kogyo Co., Ltd., H2 2012 54
Ardelyx, Inc., H2 2012 55
Sorbent Therapeutics, Inc., H2 2012 56
InVasc Therapeutics, Inc., H2 2012 57
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Stage and Molecule Type, H2 2012 64
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Drug Profile Updates 135
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Discontinued Products 156
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Dormant Products 157
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Dormant Products (Contd..1) 158
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Dormant Products (Contd..2) 159

List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2012 13
Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 19
Late Stage Products, H2 2012 21
Mid Clinical Stage Products, H2 2012 22
Early Clinical Stage Products, H2 2012 23
Discovery and Pre-Clinical Stage Products, H2 2012 24
Assessment by Monotherapy Products, H2 2012 58
Assessment by Combination Products, H2 2012 59
Assessment by Route of Administration, H2 2012 60
Assessment by Stage and Route of Administration, H2 2012 61
Assessment by Molecule Type, H2 2012 62
Assessment by Stage and Molecule Type, H2 2012 63